CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II Study Of Imatinib Mesylate (Gleevec, Formerly Known As STI571; IND 61,135, NSC #716051) In Patients With Refractory Seminoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT00042952
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:35:23.599561+00:00
Published At: 2013-01-17T00:00:00+00:00
Record Updated At: 2013-01-17
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Ovarian Dysgerminoma", "Recurrent Malignant Testicular Germ Cell Tumor", "Recurrent Ovarian Germ Cell Tumor", "Stage II Malignant Testicular Germ Cell Tumor", "Stage II Ovarian Germ Cell Tumor", "Stage III Malignant Testicular Germ Cell Tumor", "Stage III Ovarian Germ Cell Tumor", "Testicular Seminoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2013-01-17"
protocolSection.identificationModule.nctId: "NCT00042952"
protocolSection.identificationModule.officialTitle: "A Phase II Study Of Imatinib Mesylate (Gleevec, Formerly Known As STI571; IND 61,135, NSC #716051) In Patients With Refractory Seminoma"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.